Evidence map›Paper›PMID 37649125›Full record

ReviewEuropean journal of medical research2023

Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders.

Kritika Tyagi, Prachi Rai, Anuj Gautam, Harjeet Kaur, Sumeet Kapoor, Ashish Suttee, Pradeep Kumar Jaiswal, Akanksha Sharma, Gurpal Singh, Ravi Pratap Barnwal

Open access · goldAbstract readReview
In one paragraph

Review in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Neurodegenerative and Cognitive Consequences of Long COVID.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Integrating Chemo- and Bioinformatics withJournal of chemical information and modeling · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Neurological complications caused by SARS-CoV-2.Clinical microbiology reviews · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Kritika Tyagi *Department of Biophysics, Panjab University, Chandigarh, India.
Prachi Rai *Department of Biophysics, Panjab University, Chandigarh, India.
Anuj Gautam *Department of Biophysics, Panjab University, Chandigarh, India.
Harjeet Kaur *Department of Biophysics, Panjab University, Chandigarh, India.
Sumeet KapoorCentre for Biomedical Engineering, Indian Institute of Technology, New Delhi, India.
Ashish SutteeSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Pradeep Kumar JaiswalDepartment of Biochemistry and Biophysics, Texas A & M University, College Station, TX, 77843, USA.
Akanksha SharmaDepartment of Biophysics, Panjab University, Chandigarh, India. aaksgarg@gmail.com.
Gurpal SinghUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. gurpalsingh.ips@gmail.com.
Ravi Pratap BarnwalDepartment of Biophysics, Panjab University, Chandigarh, India. barnwal@pu.ac.in.
Panjab University · INIndian Institute of Technology Delhi · INLovely Professional University · INTexas A&M University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronaviruses such as Severe Acute Respiratory Syndrome coronavirus (SARS), Middle Eastern Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are associated with critical illnesses, including severe respiratory disorders. SARS-CoV-2 is the causative agent of the deadly COVID-19 illness, which has spread globally as a pandemic. SARS-CoV-2 may enter the human body through olfactory lobes and interact with the angiotensin-converting enzyme2 (ACE2) receptor, further facilitating cell binding and entry into the cells. Reports have shown that the virus can pass through the blood-brain barrier (BBB) and enter the central nervous system (CNS), resulting in various disorders. Cell entry by SARS-CoV-2 largely relies on TMPRSS2 and cathepsin L, which activate S protein. TMPRSS2 is found on the cell surface of respiratory, gastrointestinal and urogenital epithelium, while cathepsin-L is a part of endosomes.

aimThe current review aims to provide information on how SARS-CoV-2 infection affects brain function.. Furthermore, CNS disorders associated with SARS-CoV-2 infection, including ischemic stroke, cerebral venous thrombosis, Guillain-Barré syndrome, multiple sclerosis, meningitis, and encephalitis, are discussed. The many probable mechanisms and paths involved in developing cerebrovascular problems in COVID patients are thoroughly detailed. MAIN BODY: There have been reports that the SARS-CoV-2 virus can cross the blood-brain barrier (BBB) and enter the central nervous system (CNS), where it could cause a various illnesses. Patients suffering from COVID-19 experience a range of neurological complications, including sleep disorders, viral encephalitis, headaches, dysgeusia, and cognitive impairment. The presence of SARS-CoV-2 in the cerebrospinal fluid (CSF) of COVID-19 patients has been reported. Health experts also reported its presence in cortical neurons and human brain organoids. The possible mechanism of virus infiltration into the brain can be neurotropic, direct infiltration and cytokine storm-based pathways. The olfactory lobes could also be the primary pathway for the entrance of SARS-CoV-2 into the brain.

conclusionsSARS-CoV-2 can lead to neurological complications, such as cerebrovascular manifestations, motor movement complications, and cognitive decline. COVID-19 infection can result in cerebrovascular symptoms and diseases, such as strokes and thrombosis. The virus can affect the neural system, disrupt cognitive function and cause neurological disorders. To combat the epidemic, it is crucial to repurpose drugs currently in use quickly and develop novel therapeutics.

Indexed as

COVID-19SARS-CoV-2Blood-Brain BarrierBrainCentral Nervous SystemHumansACE-2Blood–brain barrierCentral nervous systemCerebrovascular diseaseCOVIDNeuroinvasionSARS-CoV-2

Identifiers

PMID37649125
PMCPMC10469568
OpenAlexW4386275033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.